Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

What symbol and exchange does Alto Neuroscience shares trade?

Alto Neuroscience trades on the NYSE stock market under the symbol ANRO.

What is Alto Neuroscience stock price doing today?

As of November 3, 2026, ANRO stock price climbed to $22.70 with 483,616 million shares trading.

What is Alto Neuroscience's Beta?

ANRO has a beta of 0.92, meaning it tends to be less sensitive to market movements. ANRO has a correlation of 0.02 to the broad based SPY ETF.

How much is Alto Neuroscience worth?

ANRO has a market cap of $890.80 million. This is considered a Small Cap stock.

What are the top ETFs holding Alto Neuroscience?

The top ETF exchange traded funds that ANRO belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.

Is Alto Neuroscience (ANRO) a good investment?

ANRO has outperformed the market in the last year with a return of +86.5%, while the SPY ETF gained +11.5%. However, in the most recent history, ANRO shares have underperformed the stock market with its stock returning -16.8% in the last 3 month period and -7.0% for the last 2 week period, while SPY has returned -0.2% and -1.9%, respectively.

What are the support and resistance levels for Alto Neuroscience (ANRO)?

ANRO support price is $21.29 and resistance is $23.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANRO shares will trade within this expected range on the day.